Monopar Therapeutics 8-K, filed Jul 12, 2021
Monopar Therapeutics (MNPR)
8-K
2021-07-12
For: 2021-07-12
View Original
Added on
April 10, 2026
About this 8-K
Monopar Therapeutics filed this 8-K on July 12, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d)
of The Securities
Exchange Act of 1934
Date of Report (Date of earliest
event reported): July 12, 2021
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
001-39070
|
|
32-0463781
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
1000 Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(847)
388-0349
Registrant’s telephone number,
including area code
N/A
(Former name or former address, if
changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each
class
|
|
Trading
Symbol(s)
|
|
Name of each
exchange on which registered
|
|
Common Stock,
$0.001 par value
|
|
MNPR
|
|
The Nasdaq Stock
Market LLC
(Nasdaq Capital
Market)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of
the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☒
On July
12, 2021, Monopar Therapeutics Inc. issued a press release
announcing the appointment
of Octávio Costa, MD, as Chief Medical
Officer. In this role, Dr. Costa will oversee global clinical
development and regulatory affairs, and will provide strategic
direction for Monopar’s pipeline.
The press
release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item 9.01 Financial Statements and
Exhibits
|
Exhibit No.
|
Description
|
|
Press Release Dated July 12,
2021
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Monopar Therapeutics Inc.
|
|
|
|
|
|
|
|
|
Date: July 12, 2021
|
By:
|
/s/ Kim R. Tsuchimoto
|
|
|
|
|
Name: Kim R. Tsuchimoto
|
|
|
|
|
Title: Chief Financial Officer, Secretary and
Treasurer
|
|
Exhibit 99.1
Monopar Appoints Octávio Costa, MD, as Chief Medical
Officer
WILMETTE,
Ill., July 12, 2021 – Monopar
Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company primarily focused on developing
proprietary therapeutics designed to extend life or improve the
quality of life for cancer patients, today announced the
appointment of Octávio Costa,
MD, as Chief Medical Officer. In this role, Dr. Costa will oversee
global clinical development and regulatory affairs, and will
provide strategic direction for Monopar’s
pipeline.
Dr. Costa joins
Monopar with over 30 years of experience overseeing clinical
development, clinical operations, development strategy and global
medical affairs. He has extensive Phase 1 through 4 clinical
development expertise as well as regulatory experience. Dr.
Costa’s previous roles include positions of increasing
responsibility in clinical development at Merck, Celgene, Novartis
and most recently as Chief Medical Officer at Rafael
Pharmaceuticals. He has played an important role in the development
and life-cycle management of significant products, including the
blockbuster product REVLIMID® (lenalidomide).
Dr. Costa earned his Doctor of Medicine from The Medical College of
Sorocaba, São Paulo.
“We are excited
to welcome Octávio, especially as our lead
program enters late-stage clinical studies,” said Chandler
Robinson, MD, Chief Executive Officer of Monopar.
“Octávio’s track record of navigating all stages
of clinical development will aid Monopar in executing our growing
clinical development pipeline.”
“I am thrilled to be joining this accomplished management
team, as Monopar’s Chief Medical Officer,” said Dr.
Costa. “My industry knowledge and expertise in moving cancer
therapies through all stages of clinical testing is well suited to
help accelerate Monopar’s pipeline of innovative mid- and
late-stage clinical programs and early drug development
candidates.”
About Monopar Therapeutics Inc.
Monopar Therapeutics is a
clinical-stage biopharmaceutical company primarily focused on
developing proprietary therapeutics designed to extend life or
improve the quality of life for cancer
patients. Monopar's pipeline consists
of Validive for the prevention of
chemoradiotherapy-induced severe oral mucositis in oropharyngeal
cancer patients; camsirubicin for the treatment of
advanced soft tissue sarcoma; a late-stage preclinical antibody,
MNPR-101, for advanced cancers and severe COVID-19; and an
early-stage camsirubicin analog, MNPR-202, for various
cancers. For more information,
visit: www.monopartx.com.
Forward-Looking
Statements
Statements contained in this press
release regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. The words
“may,” “will,” “could,”
“would,” “should,” “expect,”
“plan,” “anticipate,” “intend,”
“believe,” “estimate,”
“predict,” “project,”
“potential,” “continue,”
“target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying
words. Examples of these forward-looking statements
include statements concerning Dr. Costa providing strategic
direction for Monopar’s pipeline and Dr. Costa aiding in
executing or accelerating Monopar clinical
development. The
forward-looking statements involve risks and uncertainties
including, but not limited to Dr. Costa’s unknown future
contributions to Monopar and
the significant general risks and uncertainties surrounding the
research, development, regulatory approval, and commercialization
of therapeutics. Actual results may differ materially from those expressed
or implied by such forward-looking statements. Risks are described
more fully in Monopar's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were
made. Monopar undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made. Any forward-looking
statements contained in this press release represent
Monopar’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics
Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx
LinkedIn:
Monopar Therapeutics